Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II single-dose study of TK-002 in healthy adult men and patients with seasonal allergic conjunctivitis
jRCT2031250651Phase 2Recruiting
- Sponsor
- Teikoku Seiyaku Co., Ltd.
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of TK-002 in seasonal allergic conjunctivitis (SAC) (5 arms), sponsored by Teikoku Seiyaku Co., Ltd. Primary endpoints: Safety (Step 1), Plasma drug concentration (Step 1) and 2 more. Started Feb 2026; status: recruiting.
02
Drugs
TK-002
03
Conditions
seasonal allergic conjunctivitis (SAC)
Beyond the preview
Go deeper on jRCT2031250651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250651.